Drugs / SNV1521
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06220864 | Feb 2024 → Dec 2027 expected | neoplasm | Synnovation Therapeutics, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-10-14 | Synnovation Therapeutics, Inc. | Results Synnovation to Present SNV1521 (PARP1) Phase 1 Study Results at the European Medical Oncology (ESMO) Congress 2025 and Announces Clinical Collaboration with DualityBio to Evaluate the Combination of SNV1521 with Duality’s HER3 ADC, DB-1310 synnovationtx.com ↗
We have generated encouraging anti-tumor activity and a differentiated safety and PK profile that supports best-in-class potential and further development as a monotherapy and in combination with novel targeted and cytotoxic agents. |
All press releases naming this drug 2 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SNV1521 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06220864 ↗ |
| Route | Oral | “SNV1521 is a tablet taken orally.” NCT06220864 ↗ |